Sputnik Lite COVID-19 Vaccine Has High Safety Profile, Generates Strong Response

The study, sponsored by the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), was on the safety, tolerability and immunogenicity of the Sputnik Lite vaccine and indicated that the shot produced a strong response in both seronegative and seropositive groups.

Most of the expected adverse reactions observed during the study were mild or moderate. And, no serious adverse events were detected, the study said.

The One-Shot Sputnik Lite is authorized for use in over 15 countries, with a registration process in place in another 30 countries.

Earlier findings by the Gamleya Center, based on data from 28,000 subjects in Moscow, showed that the Sputnik Lite vaccine administered standalone during the first three months after vaccination has a 70% efficacy against infection with the delta variant of the coronavirus. The vaccine is 75% effective in subjects under 60 years of age.

The company said in a statement that the effectiveness of the Sputnik Lite vaccine as a booster against the delta version of other vaccines would be close to efficacy against the delta version of the Sputnik V vaccine: more than 83% against infection and less hospitalization. against more than 94%, the company said in a statement. .

Sputnik Lite has demonstrated a better efficacy than some two-shot vaccines, which have shown a less than 50% reduction in efficacy against the delta variant five months after injection. The study states that standalone use of Sputnik Lite provides very high efficacy against serious illness and hospitalization.

The RDIF specifically said, the vaccine has demonstrated efficacy of 78.6-83.7% among the elderly, as confirmed by the Ministry of Health of Buenos Aires, Argentina. Paraguay’s Ministry of Health found Sputnik Lite to be 93.5% effective during the country’s ongoing vaccination campaign.

The vaccine was tested as a booster shot in several clinical trials around the world. Notably, the combination of AstraZeneca/Sputnik Lite showed higher immunogenicity levels than the original AstraZeneca vaccine, the RDIF said.

RDIF and the Argentine Ministry of Health are co-sponsoring the first multivaccine combination trial targeting 2,800 subjects (560 in each of 5 provinces: the city and province of Buenos Aires, as well as Córdoba, La Rioja and San Luis).

Interim results of studies on the combination of Sputnik Lite in Argentina and vaccines manufactured by AstraZeneca, Sinopharm, Moderna and Cansino from more than 1,000 volunteers suggest that Sputnik Lite is an effective universal booster for these vaccines. The RDIF stated that each “vaccine cocktail” combination with Sputnik Lite provided a higher antibody titer on the 14th day after the second dose, as compared to the original homogenate of each vaccine (the same vaccine as the first and second doses).

Data from Argentina also demonstrated the high safety profile of using Sputnik Lite in combination with all other vaccines, with no serious adverse events following vaccination in either combination.